98%
921
2 minutes
20
Background: Preoperative hepatitis B virus (HBV) DNA level has been shown to correlate with the prognosis of patients with HBV-associated hepatocellular carcinoma (HCC) following liver resection, but its dynamic changes have not been reported. The aim of this longitudinal multicenter retrospective observational study was to describe the trajectory of HBV DNA after R0 liver resection in patients receiving antiviral therapy and to investigate its impact on clinical outcomes.
Methods: This study included patients with HBV-related HCC from nine hospitals in China who received antiviral therapy and R0 hepatectomy between 2015 and 2016. A latent class growth mixed model (LCGMM) was applied to group the trajectories of HBV DNA changes. The relative importance of each variable to predict survival was evaluated using the χ2.
Results: Six hundred and eighty-four patients with HCC who met the inclusion exclusion criteria were included. Patients were divided into 5 trajectories of HBV DNA changes using LCGMM. By combining subgroups with similar survival characteristics, patients were reclassified into three groups: slow decline, slow zeroing, and fast zeroing group, the 5-year OS rates are 34.5 %, 53.0 %, 70.9 %, respectively. Multifactorial COX regression results showed that ALBI grade, HBV reactivation, cirrhosis, maximum tumor diameter, microvascular invasion, and HBV DNA trajectory groups were independent risk factors for OS.
Conclusions: HBV DNA trajectories were associated with OS for patients with HBV-related HCC after R0 liver resection, and it is necessary to receive antiviral therapy and to monitor HBV status regularly.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ejso.2024.109492 | DOI Listing |
Microbiol Spectr
September 2025
The School of Clinical Medicine, Fujian Medical University, Fuzhou, China.
Hepatitis B virus (HBV) infection remains a major global health burden. While interferon-alpha (IFNα) therapy demonstrates antiviral and immunomodulatory effects, reliable prognostic markers for sustained response are needed. Transaminases, hematological parameters, and cytokines may serve as potential predictors, but their dynamic changes during IFNα therapy remain poorly characterized.
View Article and Find Full Text PDFFront Cell Infect Microbiol
September 2025
Core Facility of the First Hospital of Jilin University, Changchun, Jilin, China.
Diabetes and viral hepatitis, particularly hepatitis B (HBV) and hepatitis C (HCV), are significant global health burdens with complex interconnections. This review discusses the molecular mechanisms linking viral hepatitis to diabetes, focusing on inflammatory pathways, oxidative stress, and epigenetic modifications. Key findings highlight the role of STAT3 in promoting insulin resistance and β-cell apoptosis, the impact of ER stress and NOX-mediated oxidative stress on metabolic dysfunction, and the influence of epigenetic changes such as DNA methylation and histone acetylation on glucose homeostasis.
View Article and Find Full Text PDFDiagn Microbiol Infect Dis
September 2025
French National Reference Center for Hepatitis B, C and delta Viruses, Department of Virology, Hôpital Henri Mondor, Créteil, France; INSERM U955, Créteil, France. Electronic address:
Measurement of hepatitis B virus (HBV) DNA levels is the standard of care for diagnosis active HBV infection, assessing disease severity and prognosis, and guiding treatment decisions and monitoring response to therapy. In the study, the analytical and clinical performance of the ELITe InGenius System for quantifying HBV DNA was evaluated. A total of 377 of archived EDTA plasma or serum specimens were tested.
View Article and Find Full Text PDFInfect Dis Ther
September 2025
The Third Clinical Medical College, Qingdao University School of Medicine, Qingdao Municipal Hospital, Qingdao, Shandong, China.
Introduction: Oral nucleos(t)ide analogues (NAs) are widely used in managing hepatitis B virus-associated acute-on-chronic liver failure (HBV-ACLF). Among first-line therapies, entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF) are commonly prescribed. However, their comparative efficacy and safety remain unclear in HBV-ACLF.
View Article and Find Full Text PDFMedicine (Baltimore)
August 2025
Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu, China.
Nucleos(t)ide analogues (NAs) have demonstrated potent efficacy in suppressing viral replication in chronic hepatitis B (CHB). This 48-week study compared the efficacy and safety of NA treatment for CHB patients with high viral load (hepatitis B virus [HBV] deoxyribonucleic acid [DNA] > 7 log10 IU/mL). This retrospective study included 180 nucleos(t)ide-naïve CHB patients with high viral load undergoing NA monotherapy, which were stratified into 3 groups: entecavir (ETV, n = 82), tenofovir disoproxil fumarate (TDF, n = 58), and tenofovir alafenamide fumarate (TAF, n = 40).
View Article and Find Full Text PDF